AVIJF yields 2.02% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, AVIJF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AVIJF + JNJ for your $10,000?
AviChina Industry & Technology Company Limited engages in the research, development, manufacture, and sale of civil aviation products and related engineering services. It operates through three segments: Aviation Entire Aircraft Business, Aviation Ancillary System and Related Business, and Aviation Engineering Services Business. The company is involved in the development, manufacture, sale, and upgradation of defense and civil aviation products, such as helicopters, trainer and general-purpose aircrafts, and regional jets; and manufacture and sale of aviation ancillary system products, including connectors, avionics products, and its accessories. It also offers component products, including optical and electrical interconnection components and assemblies, cable assemblies, system interconnection equipment, fluid devices and equipment, etc., that are used in aviation, aerospace and other military fields, communications and data transmission, and new energy vehicles, as well as rail civil high-end manufacturing fields, such as transportation, consumer electronics, industry, energy, medical care, and intelligent equipment. In addition, the company provides various aviation power supply systems, fire extinguishing systems, environmental control systems, engine ignition systems and accessories, etc. Further, it offers aviation engineering services, such as planning, design, consultation, construction services. The company was incorporated in 2003 and is based in Beijing, the People's Republic of China. AviChina Industry & Technology Company Limited is a subsidiary of Aviation Industry Corporation of China, Ltd.
Full AVIJF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.